Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer.
cancer-related fatigue
exercise capacity
muscle atrophy
muscle fatigue
muscle force
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 01 2023
15 01 2023
Historique:
revised:
17
09
2022
received:
11
08
2022
accepted:
06
10
2022
pubmed:
19
11
2022
medline:
24
12
2022
entrez:
18
11
2022
Statut:
ppublish
Résumé
Fatigue is a hallmark of breast cancer and is associated with skeletal muscle deconditioning. If cancer-related fatigue occurs early during chemotherapy (CT), the development of skeletal muscle deconditioning and its effect on exercise capacity remain unclear. The aim of this study was to investigate the evolution of skeletal muscle deconditioning and exercise capacity in patients with early-stage breast cancer during CT. Patients with breast cancer had a visit before undergoing CT, at 8 weeks, and at the end of chemotherapy (post-CT). Body composition was determined through bioelectrical impedance analysis. Knee extensor, handgrip muscle force and fatigue was quantified by performing maximal voluntary isometric contractions and exercise capacity using the 6-min walking test. Questionnaires were also administered to evaluate quality of life, cancer-related fatigue, and physical activity level. Among the 100 patients, reductions were found in muscle mass (-2.3%, p = .002), exercise capacity (-6.7%, p < .001), and knee extensor force (-4.9%, p < .001) post-CT, which occurred within the first 8 weeks of treatment with no further decrease thereafter. If muscle fatigue did not change, handgrip muscle force decreased post-CT only (-2.5%, p = .001), and exercise capacity continued to decrease between 8 weeks and post-CT (-4.6%, p < .001). Quality of life and cancer-related fatigue were impaired after 8 weeks (p < .001) and remained stable thereafter, whereas the physical activity level remained stable during chemotherapy. Similar to cancer-related fatigue, skeletal muscle deconditioning and reduced exercise capacity occurred early during breast cancer CT. Thus, it appears essential to prevent these alterations through exercise training implemented during CT.
Sections du résumé
BACKGROUND
Fatigue is a hallmark of breast cancer and is associated with skeletal muscle deconditioning. If cancer-related fatigue occurs early during chemotherapy (CT), the development of skeletal muscle deconditioning and its effect on exercise capacity remain unclear. The aim of this study was to investigate the evolution of skeletal muscle deconditioning and exercise capacity in patients with early-stage breast cancer during CT.
METHODS
Patients with breast cancer had a visit before undergoing CT, at 8 weeks, and at the end of chemotherapy (post-CT). Body composition was determined through bioelectrical impedance analysis. Knee extensor, handgrip muscle force and fatigue was quantified by performing maximal voluntary isometric contractions and exercise capacity using the 6-min walking test. Questionnaires were also administered to evaluate quality of life, cancer-related fatigue, and physical activity level.
RESULTS
Among the 100 patients, reductions were found in muscle mass (-2.3%, p = .002), exercise capacity (-6.7%, p < .001), and knee extensor force (-4.9%, p < .001) post-CT, which occurred within the first 8 weeks of treatment with no further decrease thereafter. If muscle fatigue did not change, handgrip muscle force decreased post-CT only (-2.5%, p = .001), and exercise capacity continued to decrease between 8 weeks and post-CT (-4.6%, p < .001). Quality of life and cancer-related fatigue were impaired after 8 weeks (p < .001) and remained stable thereafter, whereas the physical activity level remained stable during chemotherapy.
CONCLUSIONS
Similar to cancer-related fatigue, skeletal muscle deconditioning and reduced exercise capacity occurred early during breast cancer CT. Thus, it appears essential to prevent these alterations through exercise training implemented during CT.
Identifiants
pubmed: 36397290
doi: 10.1002/cncr.34533
pmc: PMC10099272
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-225Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13050
pubmed: 30993802
Cancer. 2023 Jan 15;129(2):215-225
pubmed: 36397290
J Cell Mol Med. 2009 Sep;13(9B):3032-50
pubmed: 19656243
Support Care Cancer. 2019 Jan;27(1):229-238
pubmed: 29936623
J Am Heart Assoc. 2014 Jan 13;3(1):e000432
pubmed: 24419734
Am J Occup Ther. 2016 Jul-Aug;70(4):7004300010
pubmed: 27294996
J Clin Oncol. 2015 Jun 10;33(17):1918-27
pubmed: 25918291
Med Sci Sports Exerc. 2016 Nov;48(11):2228-2238
pubmed: 27015386
Respir Physiol Neurobiol. 2004 May 20;140(2):115-32
pubmed: 15134660
Front Cell Dev Biol. 2021 Sep 14;9:719643
pubmed: 34595171
J Appl Physiol (1985). 2019 Nov 1;127(5):1257-1266
pubmed: 31513446
J Psychosom Res. 2013 Jan;74(1):64-8
pubmed: 23272990
Am J Phys Med Rehabil. 2012 Sep;91(9):774-82
pubmed: 22760108
J Gerontol A Biol Sci Med Sci. 1997 Jan;52(1):B59-66
pubmed: 9008659
Lancet. 2003 Aug 23;362(9384):640-50
pubmed: 12944066
J Pain Symptom Manage. 2008 Jun;35(6):644-55
pubmed: 18358687
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1896-1907
pubmed: 35373507
Eur J Cancer. 2018 Sep;101:47-54
pubmed: 30014974
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nutr Cancer. 2018 Oct;70(7):997-1006
pubmed: 30235012
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
FASEB J. 2018 Oct;32(10):5495-5505
pubmed: 29750574
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Eur J Appl Physiol. 2011 Oct;111(10):2489-500
pubmed: 21590274
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Phys Ther. 2001 May;81(5):1102-9
pubmed: 11319935
Ecancermedicalscience. 2020 Jan 27;14:1007
pubmed: 32104209
J Natl Compr Canc Netw. 2010 Aug;8(8):904-31
pubmed: 20870636
BMC Cancer. 2019 May 20;19(1):472
pubmed: 31109309
Clin Nutr. 2010 Oct;29(5):586-91
pubmed: 20299136
Acta Physiol (Oxf). 2008 Jul;193(3):265-74
pubmed: 18266998
Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S14-21
pubmed: 23299866
Breast Cancer Res Treat. 1999 Oct;57(3):285-90
pubmed: 10617305
Geriatr Gerontol Int. 2014 Feb;14 Suppl 1:76-84
pubmed: 24450564
SAGE Open Med. 2020 Jun 17;8:2050312120922657
pubmed: 32595968
Am J Physiol Cell Physiol. 2018 Nov 1;315(5):C744-C756
pubmed: 30207784
Eur Radiol. 2020 Aug;30(8):4234-4241
pubmed: 32232787
J Clin Oncol. 2012 May 20;30(15):1805-12
pubmed: 22508807
J Pain Symptom Manage. 1999 Oct;18(4):233-42
pubmed: 10534963
Front Oncol. 2020 Aug 07;10:1304
pubmed: 32903594
J Pain Symptom Manage. 2008 Nov;36(5):468-79
pubmed: 18718735
Neural Plast. 2017;2017:1941980
pubmed: 28321339
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):305-316
pubmed: 27896952
Arch Gerontol Geriatr. 2015 Mar-Apr;60(2):252-8
pubmed: 25496605
Eur J Appl Physiol. 2004 Aug;92(4-5):602-5
pubmed: 15278355
J Appl Physiol (1985). 1992 May;72(5):1631-48
pubmed: 1601767
Physiol Rev. 2001 Oct;81(4):1725-89
pubmed: 11581501
Disabil Rehabil. 2018 Feb;40(4):486-496
pubmed: 28054496
Ann Oncol. 2016 Jun;27(6):965-974
pubmed: 26940687